Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.42 |
| ▸ | CTSB | P07858 | 12/20 | 0.42 |
| ▸ | CTSK | P43235 | 12/20 | 0.42 |
| ▸ | CTSL | P07711 | 11/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701372 | 0.86 | CTSL (0.43) | CTSSCTSBCTSKCTSLJAK2 | |
| SCHEMBL4701771 | 0.85 | CTSL (0.42) | CTSSCTSBCTSKCTSLMAPKAPK2 | |
| SCHEMBL4701788 | 0.85 | CTSS (0.43) | CTSSCTSBCTSKCTSLMAPKAPK2 | |
| SCHEMBL4698762 | 0.83 | CTSK (0.43) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4700967 | 0.82 | CTSB (0.49) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4699833 | 0.81 | CTSS (0.44) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4702476 | 0.80 | CTSK (0.40) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4704053 | 0.80 | CTSL (0.42) | CTSSCTSBCTSKCTSLJAK2 | |
| SCHEMBL4699916 | 0.79 | CTSB (0.54) | CTSSCTSBCTSKCTSL | |
| SCHEMBL4703410 | 0.78 | CTSS (0.42) | CTSSCTSBCTSKCTSLJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | claimed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | claimed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
| EP-1372655-B1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7012075-B2 | Cathepsin cysteine protease inhibitors | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198982-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSZ | CTSS 2/4885CTSB 1/4885CTSK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.